Medicine

Molecular profiling of BRAF-V600E-mutant metastatic intestines cancer in the phase\u00e2 $ 3 GUIDEPOST CRC test

.Contending rate of interests.S.K.: Stock as well as Various Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Part: AbbVie, Amal Rehabs, AstraZeneca/MedImmune, Bayer Health, Bicara Rehabs, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Venture BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Rock Health Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, Lilly, Lutris, Merck, Mirati Rehabs, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Investigation Backing: Amgen (Inst), Assortment BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Previously Pfizer. Sell as well as Other Ownership Passions: Pfizer. J.P.: Job: In The Past Pfizer. Stock and also Various Other Ownership Stakes: Pfizer. F.C.: Consulting or Advisory Role: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Analysis Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Function: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Study Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Task: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or Advisory Role: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Med), Zymeworks. Research Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Analysis Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Work: Pfizer. Stock and Other Possession Stakes: Pfizer. X.Z.: Work: Pfizer. Equity as well as Various Other Ownership Claims: Pfizer. Patents, Aristocracies, Other Intellectual Property: Johns Hopkins University. P.H.: Job: Pfizer. Sell as well as Various Other Possession Interests: Pfizer. T.X.: Work: Pfizer. Supply and also Other Ownership Claims: Pfizer. R.Y.: Consulting or even Advisory Part: Array BioPharma/Pfizer, Mirati Therapies, Zai Lab, Amgen. Study Backing: Assortment BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Function: Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Rehabs, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Therapy, TheraMyc. Other Partnership: Amgen, Variety Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Study UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de Los Angeles Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health And Wellness KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapeutics, PeerView Institute for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education Resource, Sanofi-Aventis, Servier, Taiho Drug.

Articles You Can Be Interested In